肉毒杆菌毒素治疗特发性膀胱过度活动症:实际效果和患者的期望。

Q4 Medicine
Nephrologe Pub Date : 2022-05-18 eCollection Date: 2022-03-01 DOI:10.1097/j.pbj.0000000000000164
Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva
{"title":"肉毒杆菌毒素治疗特发性膀胱过度活动症:实际效果和患者的期望。","authors":"Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva","doi":"10.1097/j.pbj.0000000000000164","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).</p><p><strong>Methods: </strong>Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.</p><p><strong>Results: </strong>A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (<i>P</i> <i>=</i> .01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (<i>P</i> = .73) nor it was related to age (<i>P</i> = .6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (<i>P</i> = .06).Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65 years old had less risk of developing a urinary tract infection (<i>P</i> = .04).</p><p><strong>Conclusion: </strong>In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"9 1","pages":"e164"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830074/pdf/","citationCount":"0","resultStr":"{\"title\":\"Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients' expectations.\",\"authors\":\"Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva\",\"doi\":\"10.1097/j.pbj.0000000000000164\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).</p><p><strong>Methods: </strong>Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.</p><p><strong>Results: </strong>A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (<i>P</i> <i>=</i> .01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (<i>P</i> = .73) nor it was related to age (<i>P</i> = .6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (<i>P</i> = .06).Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65 years old had less risk of developing a urinary tract infection (<i>P</i> = .04).</p><p><strong>Conclusion: </strong>In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.</p>\",\"PeriodicalId\":41844,\"journal\":{\"name\":\"Nephrologe\",\"volume\":\"9 1\",\"pages\":\"e164\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830074/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephrologe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/j.pbj.0000000000000164\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/j.pbj.0000000000000164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:膀胱过度活动症(OAB)是一种常见的综合征,影响着 11% 至 16% 的成年人。当一线药物治疗无效时,尿道内注射奥博妥妥毒素 A(BTX-A)可在控制症状方面发挥重要作用。本研究的主要目的是在实际临床实践中了解特发性尿崩症(iOAB)女性患者尿道内注射 100U BTX-A 的有效性和安全性:回顾性研究,基于2005年至2018年间一家三级大学医院接受BTX-A注射的136名特发性尿失禁女性患者的临床日记,无论患者有无尿失禁。只有当患者提到她在注射后有很大改善时,才被视为阳性反应,否则被视为阴性反应:90名患者(66%)在首次注射后获得了阳性反应。第一次治疗后出现阳性反应的妇女在第二次治疗后病情好转的几率是第一次的 7.5 倍(P = 0.01)。第一次注射后停止治疗既与基线时是否存在尿失禁无关(P = .73),也与年龄无关(P = .6)。在单变量分析中,没有一项评估参数能预测成功的反应,但曾因压力性尿失禁而接受过尿道中段吊带手术的妇女在首次注射后出现阳性反应的几率有降低的趋势(P = .06)。39 名妇女(29%)至少出现过一次不良反应,其中最常见的是尿路感染和排尿费力。65岁以上女性发生尿路感染的风险较低(P = .04):在实际临床实践中,BTX-A 注射是一种有效(66%)且安全的治疗方法,能够改善生活质量。此外,对第一次注射的反应似乎预示着第二次治疗的良好临床结果。这种治疗方法的限制极少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients' expectations.

Background: Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).

Methods: Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.

Results: A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (P= .01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (P = .73) nor it was related to age (P = .6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (P = .06).Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65 years old had less risk of developing a urinary tract infection (P = .04).

Conclusion: In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nephrologe
Nephrologe UROLOGY & NEPHROLOGY-
CiteScore
0.40
自引率
0.00%
发文量
25
期刊介绍: Zielsetzung der Zeitschrift Der Nephrologe bietet aktuelle und kompakte Fortbildung für alle nephrologisch tätigen Ärzt*innen in Klinik und Praxis. Inhaltlich werden sämtliche Bereiche der angewandten Nephrologie und Hypertensiologie praxisnah abgedeckt. Das Spektrum reicht von der Prävention, diagnostischen Vorgehensweisen und Komplikationsmanagement bis hin zu modernen Therapiestrategien. Umfassende Übersichtsarbeiten zu einem aktuellen Schwerpunktthema sind das Kernstück jeder Ausgabe. Im Mittelpunkt steht dabei gesichertes Wissen zu Diagnostik und Therapie mit hoher Relevanz für die tägliche Arbeit. Beiträge der Rubrik "CME Zertifizierte Fortbildung" bieten gesicherte Ergebnisse wissenschaftlicher Forschung und machen ärztliche Erfahrung für die tägliche Praxis nutzbar. Nach Lektüre der Beiträge können die Leser*innen ihr erworbenes Wissen überprüfen und online CME-Punkte erwerben. Die Rubrik orientiert sich an der Weiterbildungsordnung des Fachgebiets. Aims & Scope Der Nephrologe offers up-to-date information for all nephrologists working in practical and clinical environments and scientists who are particularly interested in issues of nephrology. The content covers all areas of applied nephrology and hypertensiology. The topics range from prevention to diagnostic approaches and management of complications to current therapy strategies. Comprehensive reviews on a specific topical issue provide evidenced based information on diagnostics and therapy. Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice. Review All articles of Der Nephrologe are reviewed. Declaration of Helsinki All manuscripts submitted for publication presenting results from studies on probands or patients must comply with the Declaration of Helsinki.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信